Beyond Transposons: TIGD1 as a Pan-Cancer Biomarker and Immune Modulator

<b>Background/Objectives</b>: <i>TIGD1</i> (Trigger Transposable Element Derived 1) is a recently identified oncogene with largely unexplored biological functions. Emerging evidence suggests its involvement in multiple cellular processes across cancer types. This study aimed to perform a comprehensive pan-cancer analysis of <i>TIGD1</i> to evaluate its expression patterns, diagnostic utility, prognostic value, and association with immunotherapy response and drug resistance. <b>Methods</b>: Transcriptomic and clinical data from TCGA and GTEx were analyzed using various bioinformatic tools. Expression profiling, survival analysis, immune correlation studies, gene set enrichment, single-cell sequencing, and drug sensitivity assessments were performed. <b>Results</b>: <i>TIGD1</i> was found to be significantly upregulated in various tumor types, with notably high expression in colon adenocarcinoma. Elevated <i>TIGD1</i> expression was associated with poor prognosis in several cancers. <i>TIGD1</i> levels correlated with key features of the tumor immune microenvironment, including immune checkpoint gene expression, TMB, and MSI, suggesting a role in modulating anti-tumor immunity. GSEA and single-cell analyses implicated <i>TIGD1</i> in oncogenic signaling pathways. Furthermore, high <i>TIGD1</i> expression was linked to resistance to several therapeutic agents, including Zoledronate, Dasatinib, and BLU-667. <b>Conclusions</b>: <i>TIGD1</i> may serve as a promising diagnostic and prognostic biomarker, particularly in colon, gastric, liver, and lung cancers. Its strong associations with immune modulation and therapy resistance highlight its potential as a novel target for precision oncology and immunotherapeutic intervention.